Does the media prefer EWTX or MGTX?

In the previous week, Edgewise Therapeutics had 1 more articles in the media than MeiraGTx. MarketBeat recorded 3 mentions for Edgewise Therapeutics and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.14 beat Edgewise Therapeutics' score of 0.75 indicating that MeiraGTx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ACAD or MGTX?

In the previous week, ACADIA Pharmaceuticals had 2 more articles in the media than MeiraGTx. MarketBeat recorded 4 mentions for ACADIA Pharmaceuticals and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.14 beat ACADIA Pharmaceuticals' score of 1.06 indicating that MeiraGTx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, MGTX or PBLS?

Parabilis Medicines has lower revenue, but higher earnings than MeiraGTx. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MeiraGTx $81.39M 15.63 -$114.20M $0.71 18.66 Parabilis Medicines N/A N/A N/A N/A N/A

Does the media refer more to MGTX or PBLS?

In the previous week, Parabilis Medicines had 3 more articles in the media than MeiraGTx. MarketBeat recorded 5 mentions for Parabilis Medicines and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.14 beat Parabilis Medicines' score of 0.58 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Parabilis Medicines 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, MGTX or TLX?

Telix Pharmaceuticals has higher revenue and earnings than MeiraGTx. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MeiraGTx $81.39M 15.63 -$114.20M $0.71 18.66 Telix Pharmaceuticals $803.79M 5.32 -$7.12M N/A N/A

Does the media favor MGTX or TLX?

In the previous week, Telix Pharmaceuticals had 21 more articles in the media than MeiraGTx. MarketBeat recorded 23 mentions for Telix Pharmaceuticals and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.14 beat Telix Pharmaceuticals' score of 0.13 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 3 Very Positive mention(s) 8 Positive mention(s) 4 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, MGTX or RLAY?

MeiraGTx has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MeiraGTx $81.39M 15.63 -$114.20M $0.71 18.66 Relay Therapeutics $15.35M 268.96 -$276.48M -$1.57 N/A

Does the media favor MGTX or RLAY?

In the previous week, MeiraGTx and MeiraGTx both had 2 articles in the media. MeiraGTx's average media sentiment score of 1.14 beat Relay Therapeutics' score of 0.77 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MeiraGTx (MGTX) Competitors

$13.25 +0.20 (+1.53%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$13.24 -0.01 (-0.04%)

As of 09/18/2026 07:30 PM Eastern

Compare

MGTX vs. EWTX, ACAD, PBLS, TLX, and RLAY

Should you buy MeiraGTx stock or one of its competitors? MeiraGTx's main competitors and comparable companies include Edgewise Therapeutics (EWTX), ACADIA Pharmaceuticals (ACAD), Parabilis Medicines (PBLS), Telix Pharmaceuticals (TLX), and Relay Therapeutics (RLAY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MeiraGTx compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and MeiraGTx (NASDAQ:MGTX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Edgewise Therapeutics presently has a consensus price target of $50.33, suggesting a potential upside of 11.06%. MeiraGTx has a consensus price target of $26.17, suggesting a potential upside of 97.48%. Given MeiraGTx's higher possible upside, analysts clearly believe MeiraGTx is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

MeiraGTx has a net margin of 19.87% compared to Edgewise Therapeutics' net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
MeiraGTx	19.87%	283.85%	29.39%

In the previous week, Edgewise Therapeutics had 1 more articles in the media than MeiraGTx. MarketBeat recorded 3 mentions for Edgewise Therapeutics and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.14 beat Edgewise Therapeutics' score of 0.75 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edgewise Therapeutics has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

MeiraGTx has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
MeiraGTx	$81.39M	15.63	-$114.20M	$0.71	18.66

67.5% of MeiraGTx shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by insiders. Comparatively, 7.4% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

MeiraGTx beats Edgewise Therapeutics on 11 of the 15 factors compared between the two stocks.

How does MeiraGTx compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and MeiraGTx (NASDAQ:MGTX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

In the previous week, ACADIA Pharmaceuticals had 2 more articles in the media than MeiraGTx. MarketBeat recorded 4 mentions for ACADIA Pharmaceuticals and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.14 beat ACADIA Pharmaceuticals' score of 1.06 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Comparatively, 7.4% of MeiraGTx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ACADIA Pharmaceuticals presently has a consensus price target of $34.36, suggesting a potential upside of 25.91%. MeiraGTx has a consensus price target of $26.17, suggesting a potential upside of 97.48%. Given MeiraGTx's higher probable upside, analysts clearly believe MeiraGTx is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

ACADIA Pharmaceuticals has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to MeiraGTx's net margin of 19.87%. MeiraGTx's return on equity of 283.85% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
MeiraGTx	19.87%	283.85%	29.39%

ACADIA Pharmaceuticals has higher revenue and earnings than MeiraGTx. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.39	$391M	$2.22	12.29
MeiraGTx	$81.39M	15.63	-$114.20M	$0.71	18.66

Summary

ACADIA Pharmaceuticals beats MeiraGTx on 9 of the 17 factors compared between the two stocks.

How does MeiraGTx compare to Parabilis Medicines?

MeiraGTx (NASDAQ:MGTX) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

MeiraGTx has a net margin of 19.87% compared to Parabilis Medicines' net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat Parabilis Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
Parabilis Medicines	N/A	N/A	N/A

Parabilis Medicines has lower revenue, but higher earnings than MeiraGTx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	15.63	-$114.20M	$0.71	18.66
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

MeiraGTx presently has a consensus target price of $26.17, indicating a potential upside of 97.48%. Parabilis Medicines has a consensus target price of $41.67, indicating a potential downside of 0.15%. Given MeiraGTx's stronger consensus rating and higher probable upside, research analysts plainly believe MeiraGTx is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Parabilis Medicines had 3 more articles in the media than MeiraGTx. MarketBeat recorded 5 mentions for Parabilis Medicines and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.14 beat Parabilis Medicines' score of 0.58 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Parabilis Medicines	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.5% of MeiraGTx shares are owned by institutional investors. 7.4% of MeiraGTx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

MeiraGTx beats Parabilis Medicines on 10 of the 11 factors compared between the two stocks.

How does MeiraGTx compare to Telix Pharmaceuticals?

MeiraGTx (NASDAQ:MGTX) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

MeiraGTx has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.17, meaning that its stock price is 117% less volatile than the broader market.

In the previous week, Telix Pharmaceuticals had 21 more articles in the media than MeiraGTx. MarketBeat recorded 23 mentions for Telix Pharmaceuticals and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.14 beat Telix Pharmaceuticals' score of 0.13 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	3 Very Positive mention(s)	8 Positive mention(s)	4 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral

Telix Pharmaceuticals has higher revenue and earnings than MeiraGTx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	15.63	-$114.20M	$0.71	18.66
Telix Pharmaceuticals	$803.79M	5.32	-$7.12M	N/A	N/A

MeiraGTx currently has a consensus price target of $26.17, indicating a potential upside of 97.48%. Telix Pharmaceuticals has a consensus price target of $20.40, indicating a potential upside of 62.03%. Given MeiraGTx's higher possible upside, analysts clearly believe MeiraGTx is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Telix Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

MeiraGTx has a net margin of 19.87% compared to Telix Pharmaceuticals' net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
Telix Pharmaceuticals	N/A	N/A	N/A

67.5% of MeiraGTx shares are owned by institutional investors. 7.4% of MeiraGTx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

MeiraGTx beats Telix Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does MeiraGTx compare to Relay Therapeutics?

MeiraGTx (NASDAQ:MGTX) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

MeiraGTx has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market.

MeiraGTx has a net margin of 19.87% compared to Relay Therapeutics' net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
Relay Therapeutics	N/A	-42.27%	-38.67%

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 7.4% of MeiraGTx shares are owned by insiders. Comparatively, 5.0% of Relay Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, MeiraGTx and MeiraGTx both had 2 articles in the media. MeiraGTx's average media sentiment score of 1.14 beat Relay Therapeutics' score of 0.77 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MeiraGTx presently has a consensus target price of $26.17, suggesting a potential upside of 97.48%. Relay Therapeutics has a consensus target price of $25.92, suggesting a potential upside of 37.56%. Given MeiraGTx's higher possible upside, equities analysts plainly believe MeiraGTx is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

MeiraGTx has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	15.63	-$114.20M	$0.71	18.66
Relay Therapeutics	$15.35M	268.96	-$276.48M	-$1.57	N/A

Summary

MeiraGTx beats Relay Therapeutics on 10 of the 16 factors compared between the two stocks.

Get MeiraGTx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGTX vs. The Competition

Export

Metric	MeiraGTx	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.25B	$3.92B	$7.24B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	18.66	14.30	275.79	25.40
Price / Sales	15.63	1,415.50	695.58	114.44
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	-189.29	15.45	10.46	6.33
Net Income	-$114.20M	-$22.86M	$3.49B	$358.33M
7 Day Performance	3.60%	-1.21%	0.59%	1.12%
1 Month Performance	-11.49%	-4.42%	-2.01%	-2.67%
1 Year Performance	75.26%	37.81%	18.09%	6.01%

MeiraGTx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGTX MeiraGTx	3.963 of 5 stars	$13.25 +1.5%	$26.17 +97.5%	+65.8%	$1.25B	$81.39M	18.66	393	Positive News
EWTX Edgewise Therapeutics	2.4456 of 5 stars	$43.22 -3.1%	$50.33 +16.5%	+191.8%	$4.70B	N/A	N/A	127	Positive News Options Volume
ACAD ACADIA Pharmaceuticals	4.436 of 5 stars	$27.00 -1.9%	$34.36 +27.3%	+10.3%	$4.65B	$1.07B	12.16	798
PBLS Parabilis Medicines	1.5724 of 5 stars	$35.59 -1.6%	$41.67 +17.1%	N/A	$4.40B	$148K	N/A	145	News Coverage
TLX Telix Pharmaceuticals	3.6382 of 5 stars	$12.93 +9.7%	$20.40 +57.8%	+37.4%	$4.39B	$890.79M	N/A	1,184	Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGTX) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MeiraGTx (MGTX) Competitors

MGTX vs. EWTX, ACAD, PBLS, TLX, and RLAY

How does MeiraGTx compare to Edgewise Therapeutics?

Summary

How does MeiraGTx compare to ACADIA Pharmaceuticals?

Summary

How does MeiraGTx compare to Parabilis Medicines?

Summary

How does MeiraGTx compare to Telix Pharmaceuticals?

Summary

How does MeiraGTx compare to Relay Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGTX vs. The Competition

MeiraGTx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MeiraGTx (MGTX) Competitors

MGTX vs. EWTX, ACAD, PBLS, TLX, and RLAY

How does MeiraGTx compare to Edgewise Therapeutics?

Do analysts recommend EWTX or MGTX?

Is EWTX or MGTX more profitable?

Does the media prefer EWTX or MGTX?

Which has more volatility & risk, EWTX or MGTX?

Which has better valuation & earnings, EWTX or MGTX?

Do institutionals & insiders hold more shares of EWTX or MGTX?

Summary

How does MeiraGTx compare to ACADIA Pharmaceuticals?

Does the media refer more to ACAD or MGTX?

Do institutionals and insiders hold more shares of ACAD or MGTX?

Do analysts prefer ACAD or MGTX?

Which has more volatility and risk, ACAD or MGTX?

Is ACAD or MGTX more profitable?

Which has better valuation & earnings, ACAD or MGTX?

Summary

How does MeiraGTx compare to Parabilis Medicines?

Is MGTX or PBLS more profitable?

Which has stronger earnings and valuation, MGTX or PBLS?

Do analysts prefer MGTX or PBLS?

Does the media refer more to MGTX or PBLS?

Do institutionals & insiders have more ownership in MGTX or PBLS?

Summary

How does MeiraGTx compare to Telix Pharmaceuticals?

Which has more risk and volatility, MGTX or TLX?

Does the media favor MGTX or TLX?

Which has better valuation and earnings, MGTX or TLX?

Do analysts prefer MGTX or TLX?

Is MGTX or TLX more profitable?

Do insiders & institutionals have more ownership in MGTX or TLX?

Summary

How does MeiraGTx compare to Relay Therapeutics?

Which has more volatility and risk, MGTX or RLAY?

Is MGTX or RLAY more profitable?

Do insiders and institutionals have more ownership in MGTX or RLAY?

Does the media favor MGTX or RLAY?

Do analysts prefer MGTX or RLAY?

Which has higher earnings & valuation, MGTX or RLAY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGTX vs. The Competition

MeiraGTx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools